Preemptive conditioning of the swine heart by H11 kinase/Hsp22 provides cardiac protection through inducible nitric oxide synthase

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 300, Issue 4, 2011, Pages

  Chen, Li ^a   Lizano, Paulo ^a   Zhao, Xin ^a   Sui, Xiangzhen ^a   Dhar, Sunil K ^b   Shen, You Tang ^a   Vatner, Dorothy E ^a   Vatner, Stephen F ^a   Depre, Christophe ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b NEW JERSEY INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Gene delivery; Myocardial ischemia; Preconditioning

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; HEAT SHOCK PROTEIN 22; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; N(G) NITROARGININE; STAT PROTEIN;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTERIAL WALL THICKENING; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY CIRCUMFLEX BRANCH; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; IMMUNOBLOTTING; ISCHEMIA; ISCHEMIC PRECONDITIONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN EXPRESSION; REGULATORY MECHANISM; REPERFUSION; SWINE; TRANSGENIC MOUSE; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; CELLS, CULTURED; CORONARY VESSELS; HEAT-SHOCK PROTEINS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MICE; MYOCARDIAL ISCHEMIA; MYOCARDIUM; MYOCYTES, CARDIAC; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE II; NITROARGININE; PROTEIN-SERINE-THREONINE KINASES; SWINE;

EID: 79955056232     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00979.2010     Document Type: Article

References (34)

1. Balligand J, Ungureanu-Longrois D, Simmons W, Pimental D, Ma- linski T, Kapturczak M, Taha Z, Lowenstein C, Davidoff A, Kelly R. Cytokine-inducible nitric oxide synthase (iNOS) expression in cardiac myocytes. Characterization and regulation of iNOS expression and detection of iNOS activity in single cardiac myocytes in vitro. J Biol Chem 269: 27580-27588, 1994.
2. Bencsik P, Kupai K, Giricz Z, Görbe A, Pipis J, Murlasits Z, Kocsis GF, Varga-Orvos Z, Puskás LG, Csonka C, Csont T, Ferdinandy P. Role of iNOS and peroxynitrite-matrix metalloproteinase-2 signaling in myocardial late preconditioning in rats. Am J Physiol Heart Circ Physiol 299: H512-H518, 2010.
3. Boengler K, Hilfiker-Kleiner D, Drexler H, Heusch G, Schulz R. The myocardial JAK/STAT pathway: from protection to failure. Pharmacol Ther 120: 172-185, 2008.
4. Bolli R. Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research. J Mol Cell Cardiol 33: 1897-1918, 2001.
5. Bolli R. The late phase of preconditioning. Circ Res 87: 972-983, 2000.
6. Bolli R, Li QH, Tang XL, Guo Y, Xuan YT, Rokosh G, Dawn B. The late phase of preconditioning and its natural clinical application-gene therapy. Heart Fail Rev 12: 189-199, 2007.
7. Danan IJ, Rashed ER, Depre C. Therapeutic potential of H11 kinase for the ischemic heart. Cardiovasc Drug Rev 25: 14-29, 2007.
8. Depre C, Hase M, Gaussin V, Zajac A, Wang L, Hittinger L, Ghaleh B, Yu X, Kudej RK, Wagner T, Sadoshima J, Vatner SF. H11 kinase is a novel mediator of myocardial hypertrophy in vivo. Circ Res 91: 1007-1014, 2002.
9. Depre C, Kim SJ, John AS, Huang Y, Rimoldi OE, Pepper JR, Dreyfus GD, Gaussin V, Pennell DJ, Vatner DE, Camici PG, Vatner SF. Program of cell survival underlying human and experimental hiber nating myocardium. Circ Res 95: 433-440, 2004.
10. Depre C, Park JY, Shen YT, Zhao X, Qiu H, Yan L, Tian B, Vatner SF, Vatner DE. Molecular mechanisms mediating preconditioning following chronic ischemia differ from those in classical second window. Am J Physiol Heart Circ Physiol 299: H752-H762, 2010.
11. Depre C, Tomlinson JE, Kudej RK, Gaussin V, Thompson E, Kim SJ, Vatner DE, Topper JN, Vatner SF. Gene program for cardiac cell survival induced by transient ischemia in conscious pig. Proc Natl Acad Sci USA 98: 9336-9341, 2001.
12. Depre C, Wang L, Sui X, Qiu H, Hong C, Hedhli N, Ginion A, Shah A, Pelat M, Bertrand L, Wagner T, Gaussin V, Vatner SF. H11 kinase prevents myocardial infarction by pre-emptive preconditioning of the heart. Circ Res 98: 280-288, 2006.
13. Ferdinandy P, Schulz R. Nitricoxide, superoxide, and peroxynitrite in myocardial ischaemia-reperfusion injury and preconditioning. Br J Pharmacol 138: 532-543, 2003.
14. Flynn C, Smoke C, Furnish E, Komalavilas P, Thresher J, Yi Z, Mandarino L, Brophy C. Phosphorylation and activation of a transduc-ible recombinant form of human HSP20 in Escherichia coli. Protein Expr Purif 52: 50-58, 2007.
15. Geng Y, Ishikawa Y, Vatner D, Wagner T, Bishop S, Vatner S, Homcy C. Apoptosis of cardiac myocytes in Gsa transgenic mice. Circ Res 84: 34-42, 1999.
16. Grines C, Rubanyi G, Kleiman N, Marrott P, Watkins M. Angiogenic gene therapy with adenovirus 5 fibroblast growth factor-4 (Ad5FGF-4): a new option for the treatment of coronary artery disease. Am J Cardiol 92: 24N-31N, 2003.
17. Grines C, Watkins M, Helmer G, Penny W, Brinker J, Marmur J, West A, Rade J, Marrott P, Hammond H, Engler R. Angiogenic gene therapy (AGENT) trial in patients with stable angina pectoris. Circulation 105: 1291-1297, 2002.
18. Grines C, Watkins M, Mahmarian J, Iskandrian A, Rade J, Marrott P, Pratt C, Kleinman N. A randomized double blind placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J Am Coll Cardiol 42: 1339-1347, 2003.
19. Gross ER, Hsu AK, Gross GJ. Opioid-induced cardioprotection occurs via glycogen synthase kinase beta inhibition during reperfusion in intact rat hearts. Circ Res 94: 960-966, 2004.
20. Guo Y, Jones WK, Xuan YT, Tang XL, Bao W, Wu WJ, Han H, Laubach VE, Ping P, Yang Z, Qiu Y, Bolli R. The late phase of ischemic preconditioning is abrogated by targeted disruption of the inducible NO synthase gene. Proc Natl Acad Sci USA 96: 11507-11512, 1999.
21. Hall G, Hasday J, Rogers T. Regulating the regulator: NF-kappaB signaling in heart. J Mol Cell Cardiol 41: 580-591, 2006.
22. Hase M, Depre C, Vatner S, Sadoshima J. H11 has dose-dependent and dual hypertrophic and proapoptotic functions in cardiac myocytes. Biochem J 388: 475-483, 2005.
23. Hedhli N, Wang L, Wang Q, Rashed E, Tian Y, Sui X, Madura K, Depre C. Proteasome activation during cardiac hypertrophy by the chap-erone H11 kinase/Hsp22. Cardiovasc Res 77: 497-505, 2008.
24. Kappe G, Verschuure P, Philipsen R, Staalduinen A, Van den Bogaart P, Boelens W, De Jong W. Characterization of two novel human small heat shock proteins: protein kinase-related HspB8 and testis-specific HspB9. Biochim Biophys Acta 1520: 1-6, 2001.
25. Kurosaki K, Ikeda U, Maeda Y, Shimada K. Carvedilol stimulates nitric oxide synthesis in rat cardiac myocytes. J Mol Cell Cardiol 32: 333-339, 2000.
26. Rutanen J, Rissanen TT, Markkanen JE, Gruchala M, Silvennoinen P, Kivela A, Hedman A, Hedman M, Heikura T, Orden MR, Stacker SA, Achen MG, Hartikainen J, Yla-Herttuala S. Adenoviral catheter-mediated intramyocardial gene transfer using the mature form of vascular endothelial growth factor-D induces transmural angiogenesis in porcine heart. Circulation 109: 1029-1035, 2004.
27. Shen YT, Depre C, Yan L, Park JY, Tian B, Jain K, Chen L, Zhang Y, Kudej RK, Zhao X, Sadoshima J, Vatner DE, Vatner SF. Repetitive ischemia by coronary stenosis induces a novel window of ischemic preconditioning. Circulation 118: 1961-1969, 2008.
28. Smith C, Yu Y, Kulka M, Aurelian L. A novel human gene similar to the protein kinase (PK) coding domain of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) codes for a serine-threonine PK and is expressed in melanoma cells. J Biol Chem 275: 25690-25699, 2000.
29. Sui X, Li D, Qiu H, Gaussin V, Depre C. Activation of the bone morphogenetic protein receptor by H11 kinase/Hsp22 promotes cardiac cell growth and survival. Circ Res 104: 887-895, 2009.
30. Takano H, Manchikalapudi S, Tang XL, Qiu Y, Rizvi A, Jadoon AK, Zhang Q, Bolli R. Nitric oxide synthase is the mediator of late preconditioning against myocardial infarction in conscious rabbits. Circulation 98: 441-449, 1998.
31. Vitale J, Qiu H, Depre C. Pre-emptive conditioning of the ischemic heart. Cardiovasc Hematol Agents Med Chem 6: 92-104, 2008.
32. Wang Y, Guo Y, Zhang SX, Wu WJ, Wang J, Bao W, Bolli R. Ischemic preconditioning upregulates inducible nitric oxide synthase in cardiac myocyte. J Mol Cell Cardiol 34: 5-15, 2002.
33. Yellon D, Downey J. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev 83: 1113-1151, 2003.
34. Zhang J, Ping P, Vondriska TM, Tang XL, Wang GW, Cardwell EM, Bolli R. Cardioprotection involves activation of NF-kappaB via PKC-dependent tyrosine and serine phosphorylation of IkappaB-alpha. Am J Physiol Heart Circ Physiol 285: H1753-H1758, 2003.